Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here using clinically relevant murine prostate cancer models, we investigated the significance of β-catenin activation in prostate cancer progression and treatment resistance.
|
31719098 |
2020 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, ZNF433 was the binding partner of beta-catenin and activated beta-catenin/TCF signaling in prostate cancer.
|
30774387 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
β-catenin has also been reported to form complex with AR and thus augment AR signaling in PCa.
|
31027362 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, CDC20 combined with CD44 or β-catenin can serve as an important indicator for prognosis of patients with prostate cancer.
|
30904606 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Therefore, targeting β-catenin expression could be a useful approach to treating prostate cancer.
|
30819007 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To understand the role of miR-129-5p and ZIC2 in PCa, DU145 cells were transfected with mimic or inhibitor of miR-129-5p, or si-ZIC2 and the expression of Wnt, β-catenin, E-cadherin, vimentin, N-cadherin, vascular endothelial growth factor (VEGF), and CD31, as well as the extent of β-catenin phosphorylation was determined.
|
31649488 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
MicroRNA-95-3p promoted the development of prostatic cancer via regulating DKK3 and activating Wnt/β-catenin pathway.
|
30779066 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Knockdown of the long noncoding RNA HOTTIP inhibits cell proliferation and enhances cell sensitivity to cisplatin by suppressing the Wnt/β-catenin pathway in prostate cancer.
|
30809864 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Downregulation of RORα1 and upregulation of Wnt/β-catenin target genes were correlated in prostate cancer patients.
|
30987323 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we found that curcumin significantly upregulated the expression of miR-34a, along with the downregulated expression of β-catenin and c-myc in three prostate cancer cell lines.
|
31042325 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Since growing evidence demonstrates that WNT/β-catenin signaling plays an important role in CRPC, the antitumor activity and mechanism of action of CWP232291, a small molecule β-catenin inhibitor, were investigated in prostate cancer.
|
31387608 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The β-catenin:TCF interaction plays a critical role in the Wnt signaling pathway which is over-activated in multiple cancers, including prostate cancer.
|
30352998 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pharmacological inhibition of β-catenin nuclear translocation using compounds ICG001 and IWR-1 restored HLEC tight-junction integrity and inhibited prostate cancer cell transendothelial migration in vitro and lung metastasis in vivo.
|
29755115 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, targeting clinically significant PCa with high levels of δ-catenin with anti-androgen and anti β-catenin combination therapy may prevent progression of the disease to a castration-resistant state and, thus, represents a promising therapeutic strategy.
|
29849951 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
CLCA2 promoted PCa cell adhesion inhibiting epithelial-mesenchymal transition (EMT) and activating CTNNB1 together with epithelial marker (CDH1) induction, and mesenchymal markers (SNAI2 and TWIST1) repression.
|
29536528 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that FAM46B was downregulated but that β-catenin was upregulated in patients with PC.
|
30532005 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
δ-Catenin, a member of the p120-catenin subfamily of armadillo proteins, reportedly increases during the late stage of prostate cancer.
|
29629558 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, it was demonstrated that miR‑138 negatively regulated the Wnt/β‑catenin pathway activation in prostate cancer.
|
29257301 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results suggest a role for TRPM4 channels in β-catenin oncogene signaling and underlying mechanisms, highlighting this ion channel as a new potential target for future therapies in prostate cancer.
|
28614631 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
β‑catenin nuclear translocation induced by HIF‑1α overexpression leads to the radioresistance of prostate cancer.
|
29658569 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overactivation of beta-catenin/TCF signaling in prostate cancer is very common.
|
30125550 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results reveal that suppression of Capn4 by miR-520b inhibits the growth and invasion of prostate cancer cells associated with downregulated Wnt/β-catenin signaling, indicating an important role of the miR-520b/Capn4/Wnt/β-catenin regulation axis in the molecular pathogenesis of prostate cancer.
|
30241050 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent genome-wide analysis of prostate cancer metastases illustrate the importance of the Wnt/β-catenin pathway in prostate cancer and compel us to reexamine the interaction of the AR and Wnt/β-catenin signaling pathways.
|
28189566 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings establish that AMPK/GSK3β/β-catenin cascade-triggered CEMIP overexpression might promote migration and invasion in anoikis-resistant PCa cells by enhancing PDK4-associated metabolic reprogramming, which may provide a novel, promising therapeutic target for the treatment of advanced PCa.-Zhang, P., Song, Y., Sun, Y., Li, X., Chen, L., Yang, L., Xing, Y. AMPK/GSK3β/β-catenin cascade-triggered overexpression of CEMIP promotes migration and invasion in anoikis-resistant prostate cancer cells by enhancing metabolic reprogramming.
|
29505302 |
2018 |